StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)

Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%

Gilead Sciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Gilead Sciences's EV/EBITDA was 17.0× on Jul 31, 2026, against 19.1× a year earlier. Over the last 5 years it ranged from 9.3× to 169.4×, with a median of 16.6×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 202617.0×+0.8
2025Dec 31, 202516.2×−145.9
2024Dec 31, 2024162.1×+147.7
2023Dec 29, 202314.4×−6.8
2022Dec 30, 202221.2×+11.5
2021Dec 31, 20219.7×−21.5
2020Dec 31, 202031.2×+11.8
2019Dec 31, 201919.4×+10.8
2018Dec 31, 20188.6×+2.6
2017Dec 29, 20176.0×+0.3
2016Dec 30, 20165.7×−1.6
2015Dec 31, 20157.4×−4.7
2014Dec 31, 201412.0×−15.2
2013Dec 31, 201327.2×+10.6
2012Dec 31, 201216.7×+9.0
2011Dec 30, 20117.7×+0.5
2010Dec 31, 20107.2×−4.7
2009Dec 31, 200912.0×–

More Gilead Sciences figures

See a number that looks wrong?